Free Trial

Chromocell Therapeutics (CHRO) Competitors

Chromocell Therapeutics logo
$1.34 +0.08 (+6.35%)
Closing price 07/1/2025
Extended Trading
$1.34 0.00 (0.00%)
As of 07/1/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CHRO vs. MRSN, CLNN, LTRN, KZR, OKUR, RNTX, ESLA, BDRX, KALA, and EGRX

Should you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Mersana Therapeutics (MRSN), Clene (CLNN), Lantern Pharma (LTRN), Kezar Life Sciences (KZR), OnKure Therapeutics (OKUR), Rein Therapeutics (RNTX), Estrella Immunopharma (ESLA), Biodexa Pharmaceuticals (BDRX), KALA BIO (KALA), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry.

Chromocell Therapeutics vs. Its Competitors

Mersana Therapeutics (NASDAQ:MRSN) and Chromocell Therapeutics (NYSE:CHRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Chromocell Therapeutics has lower revenue, but higher earnings than Mersana Therapeutics. Chromocell Therapeutics is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mersana Therapeutics$40.50M1.01-$69.19M-$0.59-0.55
Chromocell TherapeuticsN/AN/A-$7.38M-$1.24-1.08

Mersana Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Chromocell Therapeutics has a beta of 3.63, suggesting that its stock price is 263% more volatile than the S&P 500.

Mersana Therapeutics currently has a consensus target price of $5.20, suggesting a potential upside of 1,490.21%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Mersana Therapeutics is more favorable than Chromocell Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mersana Therapeutics
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.00
Chromocell Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Chromocell Therapeutics has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -217.63%. Chromocell Therapeutics' return on equity of 0.00% beat Mersana Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mersana Therapeutics-217.63% -990.16% -48.87%
Chromocell Therapeutics N/A N/A -453.90%

In the previous week, Mersana Therapeutics had 3 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 3 mentions for Mersana Therapeutics and 0 mentions for Chromocell Therapeutics. Chromocell Therapeutics' average media sentiment score of 0.00 beat Mersana Therapeutics' score of -0.42 indicating that Chromocell Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Mersana Therapeutics Neutral
Chromocell Therapeutics Neutral

93.9% of Mersana Therapeutics shares are owned by institutional investors. Comparatively, 78.0% of Chromocell Therapeutics shares are owned by institutional investors. 13.0% of Mersana Therapeutics shares are owned by insiders. Comparatively, 16.4% of Chromocell Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Mersana Therapeutics beats Chromocell Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Chromocell Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CHRO vs. The Competition

MetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$8.69M$207.74M$5.46B$20.45B
Dividend YieldN/AN/A5.24%3.72%
P/E Ratio-1.08N/A27.0127.80
Price / SalesN/A259.79380.1449.81
Price / CashN/A22.4426.2118.22
Price / Book-0.815.707.994.58
Net Income-$7.38M-$96.61M$3.16B$982.91M
7 Day Performance-90.07%1.15%3.69%1.31%
1 Month Performance-88.04%0.30%2.91%4.85%
1 Year Performance-87.36%10.37%34.30%14.09%

Chromocell Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CHRO
Chromocell Therapeutics
N/A$1.34
+6.3%
N/A-89.1%$8.69MN/A-1.084Gap Up
High Trading Volume
MRSN
Mersana Therapeutics
3.6704 of 5 stars
$0.28
-5.1%
$5.20
+1,750.5%
-83.4%$35.02M$40.50M-0.48150
CLNN
Clene
2.6626 of 5 stars
$3.87
-1.0%
$40.00
+933.1%
-44.5%$34.93M$340K-0.96100
LTRN
Lantern Pharma
2.4493 of 5 stars
$3.14
-0.8%
$25.00
+697.4%
-28.1%$33.80MN/A-1.7020Positive News
Gap Up
KZR
Kezar Life Sciences
4.0422 of 5 stars
$4.43
-3.4%
$39.50
+792.7%
-21.6%$32.33MN/A-0.4160Negative News
OKUR
OnKure Therapeutics
3.1247 of 5 stars
$2.39
flat
$32.33
+1,252.9%
N/A$32.29MN/A-0.45N/A
RNTX
Rein Therapeutics
N/A$1.45
+3.6%
N/AN/A$32.12MN/A-0.519
ESLA
Estrella Immunopharma
2.1967 of 5 stars
$0.88
-8.9%
$16.00
+1,728.6%
-27.1%$31.65MN/A-3.37N/APositive News
Gap Down
BDRX
Biodexa Pharmaceuticals
N/A$0.86
-1.2%
N/AN/A$31.24M$470K0.0020Upcoming Earnings
KALA
KALA BIO
3.4724 of 5 stars
$4.78
+0.5%
$13.50
+182.2%
-23.5%$31.10M$3.89M-0.5930High Trading Volume
EGRX
Eagle Pharmaceuticals
N/A$2.36
-18.6%
N/A-45.5%$30.65M$257.55M0.00100

Related Companies and Tools


This page (NYSE:CHRO) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners